KaydedilenlerDerginizi ekleyin

Dergiler / GORM:Gynecology Obstetrics & Reproductive Medicine / 2009 / Cilt: 15 - Sayı: 3

Effectiveness of different treatment modalities in postmenopausal women with osteopenia and osteoporosis

Postmenopozal osteopeni ve osteoporoz tedavisinde farklı tedavi modalitelerinin etkinliği çalışması

Berfu DEMİR
ENİS ÖZKAYA
Nilgün ÖZTÜRK
Burak KARADAĞ
Ali HABERAL
Sayfa
153–156
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

BULGULAR: Antirezorptif ve kombine tedavi alan grupta HT grubuna kıyasla anlamlı fark saptandı (P = 0.001, P = 0.001).

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:AMAÇ: Farklı antirezorptif ajanların ve hormon tedavisinin (HT) T skoru üzerine etkisi araştırıldı.
📊
Temel Bulgular & Veri:GEREÇ VE YÖNTEM: Postmenopozal 1073 hasta çalışmaya dahil edildi.
💡
Sonuç & Katkı:BULGULAR: Antirezorptif ve kombine tedavi alan grupta HT grubuna kıyasla anlamlı fark saptandı (P = 0.001, P = 0.001).
🔬Tür:Araştırma Makalesi
📍Kapsam:1073 hasta
⚙️Değişkenler:Alan Parametreleri

Özet

AMAÇ: Farklı antirezorptif ajanların ve hormon tedavisinin (HT) T skoru üzerine etkisi araştırıldı. GEREÇ VE YÖNTEM: Postmenopozal 1073 hasta çalışmaya dahil edildi. Hastalar aldıkları tedavilere göre HT, antirezorptif, HT ve antirezorptif tedavi kombine ve kontrol grubu olarak dört gruba ayrıldılar. Tedaviye yanıt T skorundaki değişimle değerlendirildi. Ayrıca hormon tedavisi ve antirezorptif tedavi grubunda alt grup analizi yapıldı. BULGULAR: Antirezorptif ve kombine tedavi alan grupta HT grubuna kıyasla anlamlı fark saptandı (P = 0.001, P = 0.001). Hormon tedavisi (östrojen:170, östrojen-progestin: 234, tibolon:136) grubunda kontrol grubuna göre T skorundaki değişim anlamlı idi (P = 0.001, P = 0.001, P = 0.001). Antirezorptif tedavi (etidronat: 165, alendronat: 94, risedronat:11, kalsitonin: 10) alan grupta da kontrol grubuna göre anlamlı değişim saptandı (P = 0.001, P = 0.001, P = 0.001, P = 0.001) . Alt grup analizinde T skorundaki değişim sadece alendronat ve etidronat arasında bulundu (P=0.001). SONUÇ: Postmenopozal osteopeni-osteoporozlu olgularda, hormon tedavisi ve antirezorptif tedavi kombinasyonu tek ajan tedaviye kıyasla T skoru üzerinde daha etkilidir.

Abstract

OBJECTIVE: The aim of this study was to evaluate the efficacy of different antiresorptive agents and hormone therapy (HT) on T score and to compare their effectiveness with each other. STUDY DESIGN: Medical records of 1073 postmenopausal women were reviewed. Patients were classified into four groups; hormone therapy, antiresorptive therapy (AT), combined HT and AT and control. Groups were evaluated with their response to treatment modality by measuring the changes on T score. Also, patients of HT and AT groups were compared with each other according to the effectiveness of the treatment on T score changes. RESULTS: Treatment related increase in T score was significantly different in HT-AT and AT groups compared with the HT group (P=0.001, P=0.001). Within the HT group (estrogen: 170, estrogen-progestin: 234, tibolone: 136) the alteration on T score was statistically significant compared to the control group (P=0.001, P=0.001, P = 0.001). Within the AT group (etidronate: 165, alendronate: 94, risedronate : 11, calcitonin: 10) all agents were significantly different compared to the control group according to the alterations on T score (P=0.001, P=0.001, P=0.001, P = 0.001). When the change in T score was compared, the alendronate group was significantly different than the etidronate group (P=0.001). CONCLUSION: Hormone therapy combined with AT and AT alone was found to be superior to HT in terms of increments in T score values in postmenopausal women with osteopenia and osteoporosis.

🔖

Bu Makaleye Atıf Yap

DEMİR, B., ÖZKAYA, E., ÖZTÜRK, N., KARADAĞ, B., HABERAL, A. (2009). Effectiveness of different treatment modalities in postmenopausal women with osteopenia and osteoporosis. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 15 - Sayı: 3, 153–156. https://ajindex.com/articles/227079

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. NIH Consensus Development panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy JAMA 2001
  2. 95 2. Ng MYM, Sham PC, Paterson AD, Chan V, Kung AWC Effect of environmental factors and gender on the heritability of bone mineral density and bone size. Annals of Human Genetics 2006
  3. 438 3. Marshall D, Johnell O, Wedel H Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996
  4. 1259 4. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Blavk D, Adachi J, Shea B, Tugwell P, Guyatt G Metaanalysis of Alendronate for the treatment of postmenopausal women. Endocrine Reviews 2002
  5. 23(4): 508-516 5. Reginster JY. Prevention postmenopausal osteoporosis with pharmacological therapy: practice and possibilities. J Int Med 2004
  6. 628 6. Chesnut CH 3rd, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L Salmon calcitonin: a review of current end future therapeutic indications. Osteoporosis Int 2008
  7. 91 7. Von Holst T Alternatives to hormone replacement therapy: raloxifene and tibolone. Z Arztl Fortbild Qualitatssich 94(3): 205-9 8. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A (2002) Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2000
  8. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996
  9. Cauley JA, Robbins J, Chen Z, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003
  10. Torgerson DJ, Bell-Syer SE Hormone replacement and prevention of nonvertebral fractures. J Am Med Assoc 2001
  11. 2897 12. Tremollieres FA, Pouilles JM, Ribot C Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 2001
  12. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G Meta-analysis of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the